stockrowTarsus Pharmaceuticals, Inc.
TARS Healthcare Biotechnology
Tarsus Pharmaceuticals, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $451.4 million, up 146.7% from fiscal 2024.
- Revenue
- +63.9%
- EPS
- −4,699.1%
- Free cash flow
- −144.1%
- Total debt
- +0.90%
Quarter to September 2026, against a year earlier
Follow TARS
Alert me
Tarsus Pharmaceuticals, Inc. (TARS) Shares outstanding
Tarsus Pharmaceuticals, Inc.'s shares outstanding at the end of fiscal 2025 was $41.8M, up 11.1% from $37.6M in fiscal 2024. At the end of the quarter to 30 September 2026 it was $46.4M. Over the past ten years it has ranged from $2.4M (fiscal 2019) to $41.8M (fiscal 2025) — the current reading is the highest in ten years. Tarsus Pharmaceuticals, Inc. ranks 306th of 600 Biotechnology companies by shares outstanding.
Shares outstanding, annual
Embed this chart
Annual newest first
| Period | Shares outstanding | Change |
|---|---|---|
| FY2025 | $41.8M | 11.11% |
| FY2024 | $37.6M | 27.98% |
| FY2023 | $29.4M | 19.35% |
| FY2022 | $24.6M | 19.78% |
| FY2021 | $20.6M | 231.14% |
| FY2020 | $6.2M | 162.67% |
| FY2019 | $2.4M | (87.89%) |
| FY2018 | $19.5M | — |
Quarterly newest first
| Period | Shares outstanding | Change |
|---|---|---|
| Sep 2026 | $46.4M | 6.98% |
| Jun 2026 | $43.4M | 1.02% |
| Mar 2026 | $43.0M | 2.81% |
| Dec 2025 | $41.8M | (1.93%) |
| 24 more quarters | Free account |
Against its own ten years
Shares outstanding against peers
| Company | Shares outstanding |
|---|---|
| DNLI Denali Therapeutics Inc. compare | $192.1M |
| ACAD ACADIA Pharmaceuticals Inc. compare | $175.5M |
| DYN Dyne Therapeutics, Inc. compare | $165.5M |
| VKTX Viking Therapeutics, Inc. compare | $118.1M |
| VRDN Viridian Therapeutics, Inc. compare | $107.9M |
| ELVN Enliven Therapeutics, Inc. compare | $66.2M |
| CELC Celcuity, Inc. compare | $54.8M |
| TARS Tarsus Pharmaceuticals, Inc. | $46.4M |
| TLX Telix Pharmaceuticals Limited compare | — |
What Shares outstanding is
Shares (Diluted, Weighted) tells an investor how many shares a company’s earnings are spread across once potential new shares are counted.
Reported line item
More on TARS
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement